Vitadio, founded in 2019 in Prague, is a leader in digital therapeutics for type 2 diabetes and prediabetes. The company uses artificial intelligence combined with evidence-based medicine to offer cutting-edge therapy, improving patient outcomes. With offices in Prague and Berlin, Vitadio currently serves patients across three European countries, with plans for further expansion.
EIT and Investor Support
- EIT Program: Supported by EIT Health.
- Key Achievements: Gained visibility, access to a network of experts, and valuable connections across European markets.
Key Milestones
- Founded in 2019 to address the growing challenge of type 2 diabetes and prediabetes.
- Developed a mobile app that provides personalized digital care programs.
- Expanded across three European countries with a growing customer base.
Highlights
- Vitadio’s mobile app empowers patients with personalized care programs.
- Provides a scalable support system with registered dietitians.
- Clinically validated solution helps patients achieve better health outcomes while offering cost-effective models for health insurers.
- Supported by EIT Health’s network, boosting its expansion and impact in European markets.
The Impact
Vitadio is transforming diabetes care by bridging the gap between doctor visits with its mobile app. Patients receive continuous, personalized support that improves health outcomes, while physicians gain real-time monitoring tools, and health insurers benefit from a cost-effective solution.
Technology Highlights
Vitadio’s AI-driven mobile app provides a scalable, clinically validated solution for managing type 2 diabetes and prediabetes. It enhances patient care, improves health outcomes, and reduces the cost burden of diabetes management.